Cerus Shareholder Opposes Director Nominations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: Newsfilter
- Shareholder Voting Intent: Significant shareholder Bradley L. Radoff of Cerus Corporation announced his intention to withhold support for the reelection of CEO William Greenman and Compensation Committee Chair Ann Lucena at the 2026 annual meeting, reflecting strong dissatisfaction with the company's failure to achieve profitability and negative returns over the past decade.
- Equity Dilution Issue: Over the past ten years, Cerus's share count has nearly doubled from 101,710,815 in 2016 to 200,316,000 in 2026, leading to shareholder value dilution despite the company having a market-leading product in the INTERCEPT Blood System.
- Governance Structure Criticism: Cerus maintains a classified board structure, criticized by independent proxy advisors as a
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CERS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CERS
Wall Street analysts forecast CERS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.920
Low
4.00
Averages
4.50
High
5.00
Current: 2.920
Low
4.00
Averages
4.50
High
5.00
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cerus Shareholder Opposes Director Nominations
- Shareholder Voting Intent: Significant shareholder Bradley L. Radoff of Cerus Corporation announced his intention to withhold support for the reelection of CEO William Greenman and Compensation Committee Chair Ann Lucena at the 2026 annual meeting, reflecting strong dissatisfaction with the company's failure to achieve profitability and negative returns over the past decade.
- Equity Dilution Issue: Over the past ten years, Cerus's share count has nearly doubled from 101,710,815 in 2016 to 200,316,000 in 2026, leading to shareholder value dilution despite the company having a market-leading product in the INTERCEPT Blood System.
- Governance Structure Criticism: Cerus maintains a classified board structure, criticized by independent proxy advisors as a
See More
Cerus Reports Strong Q1 2026 Earnings with Raised Guidance
- Significant Revenue Growth: Cerus reported Q1 2026 product revenue of $53.7 million, a 24% increase year-over-year, driven by strong performance in its global platelet franchise and accelerating demand in the U.S. IFC business, indicating enhanced competitive positioning in the market.
- Raised Full-Year Guidance: The company raised its full-year 2026 product revenue guidance to $227 million to $231 million and IFC revenue guidance to $22 million to $24 million, reflecting expected year-over-year growth of 10% to 12% for products and 30% to 40% for IFC compared to 2025.
- International Market Expansion: Under the Blood Centers of America agreement, Cerus is already witnessing early traction, including increased activity from existing customers and new agreements, suggesting significant room for growth in international market penetration.
- Leadership Transition: Cerus' current CEO William Greenman announced his retirement during the earnings call, officially passing the baton to Vivek Jayaraman, marking a stable transition in leadership as the company continues to evolve strategically.
See More
Cerus Raises 2026 Product Revenue Guidance Amid Strong Q1 Results
- Earnings Beat: Cerus reported a Q1 GAAP EPS of -$0.01, beating expectations by $0.03, with revenue of $59.9 million reflecting a 22.5% year-over-year increase and surpassing estimates by $8.72 million, indicating strong market performance.
- Cash Position: As of March 31, 2026, Cerus had cash and short-term investments totaling $80.4 million, a slight decrease from $82.9 million at December 31, 2025, demonstrating stability in financial management.
- Guidance Upgrade: The company raised its 2026 product revenue guidance to a range of $227 million to $231 million, projecting a growth of 10% to 12% from 2025, reflecting increased confidence in future market demand.
- IFC Revenue Outlook: The updated guidance includes an IFC revenue expectation of $22 million to $24 million for 2026, up from the previous range of $20 million to $22 million, highlighting growth potential in specific product lines.
See More
Cerus Scheduled to Announce Q1 Earnings on April 30
- Earnings Announcement: Cerus (CERS) is set to announce its Q1 2023 earnings on April 30 after market close, with consensus EPS estimate at -$0.04 and revenue expected at $51.18 million, reflecting a 4.7% year-over-year growth.
- Earnings Estimate Changes: Over the last three months, Cerus has seen 0 upward revisions and 1 downward revision in EPS estimates, while revenue estimates have experienced 2 upward revisions with no downward adjustments, indicating market confidence in revenue growth.
- Executive Appointment: Cerus has appointed Vivek Jayaraman as CEO, which may bring new strategic direction and leadership to the company, potentially enhancing its business development efforts.
- Historical Performance Review: In Q4 2025, Cerus reported a GAAP EPS of -$0.01 and revenue of $64.6 million, reflecting the company's market performance and future growth potential.
See More
Cerus Corporation Appoints New CEO Vivek Jayaraman
- Executive Appointment: Cerus Corporation has appointed Vivek Jayaraman as CEO effective July 1, 2026, who has been with the company since 2016 and has served as COO since 2020, showcasing strong leadership capabilities.
- Revenue Growth: Under Jayaraman's leadership, Cerus has grown its annual product revenue from less than $40 million to over $200 million by 2025, indicating robust market performance and sustained growth potential.
- Future Outlook: Cerus expects a 14% increase in revenue for 2025 and has provided guidance for 2026, reflecting the company's confidence in its strategic planning and future development.
- Market Reaction: Following the announcement, Cerus's stock price experienced a slight after-hours decline of 0.0% to $1.805, indicating a cautious market sentiment regarding the new CEO's appointment.
See More
Cerus (CERS) Q4 2025 Earnings Call Transcript
See More
Cerus Shareholder Opposes Director Nominations
- Shareholder Voting Intent: Significant shareholder Bradley L. Radoff of Cerus Corporation announced his intention to withhold support for the reelection of CEO William Greenman and Compensation Committee Chair Ann Lucena at the 2026 annual meeting, reflecting strong dissatisfaction with the company's failure to achieve profitability and negative returns over the past decade.
- Equity Dilution Issue: Over the past ten years, Cerus's share count has nearly doubled from 101,710,815 in 2016 to 200,316,000 in 2026, leading to shareholder value dilution despite the company having a market-leading product in the INTERCEPT Blood System.
- Governance Structure Criticism: Cerus maintains a classified board structure, criticized by independent proxy advisors as a
See More
Cerus Reports Strong Q1 2026 Earnings with Raised Guidance
- Significant Revenue Growth: Cerus reported Q1 2026 product revenue of $53.7 million, a 24% increase year-over-year, driven by strong performance in its global platelet franchise and accelerating demand in the U.S. IFC business, indicating enhanced competitive positioning in the market.
- Raised Full-Year Guidance: The company raised its full-year 2026 product revenue guidance to $227 million to $231 million and IFC revenue guidance to $22 million to $24 million, reflecting expected year-over-year growth of 10% to 12% for products and 30% to 40% for IFC compared to 2025.
- International Market Expansion: Under the Blood Centers of America agreement, Cerus is already witnessing early traction, including increased activity from existing customers and new agreements, suggesting significant room for growth in international market penetration.
- Leadership Transition: Cerus' current CEO William Greenman announced his retirement during the earnings call, officially passing the baton to Vivek Jayaraman, marking a stable transition in leadership as the company continues to evolve strategically.
See More
Cerus Raises 2026 Product Revenue Guidance Amid Strong Q1 Results
- Earnings Beat: Cerus reported a Q1 GAAP EPS of -$0.01, beating expectations by $0.03, with revenue of $59.9 million reflecting a 22.5% year-over-year increase and surpassing estimates by $8.72 million, indicating strong market performance.
- Cash Position: As of March 31, 2026, Cerus had cash and short-term investments totaling $80.4 million, a slight decrease from $82.9 million at December 31, 2025, demonstrating stability in financial management.
- Guidance Upgrade: The company raised its 2026 product revenue guidance to a range of $227 million to $231 million, projecting a growth of 10% to 12% from 2025, reflecting increased confidence in future market demand.
- IFC Revenue Outlook: The updated guidance includes an IFC revenue expectation of $22 million to $24 million for 2026, up from the previous range of $20 million to $22 million, highlighting growth potential in specific product lines.
See More
Cerus Scheduled to Announce Q1 Earnings on April 30
- Earnings Announcement: Cerus (CERS) is set to announce its Q1 2023 earnings on April 30 after market close, with consensus EPS estimate at -$0.04 and revenue expected at $51.18 million, reflecting a 4.7% year-over-year growth.
- Earnings Estimate Changes: Over the last three months, Cerus has seen 0 upward revisions and 1 downward revision in EPS estimates, while revenue estimates have experienced 2 upward revisions with no downward adjustments, indicating market confidence in revenue growth.
- Executive Appointment: Cerus has appointed Vivek Jayaraman as CEO, which may bring new strategic direction and leadership to the company, potentially enhancing its business development efforts.
- Historical Performance Review: In Q4 2025, Cerus reported a GAAP EPS of -$0.01 and revenue of $64.6 million, reflecting the company's market performance and future growth potential.
See More
Cerus Corporation Appoints New CEO Vivek Jayaraman
- Executive Appointment: Cerus Corporation has appointed Vivek Jayaraman as CEO effective July 1, 2026, who has been with the company since 2016 and has served as COO since 2020, showcasing strong leadership capabilities.
- Revenue Growth: Under Jayaraman's leadership, Cerus has grown its annual product revenue from less than $40 million to over $200 million by 2025, indicating robust market performance and sustained growth potential.
- Future Outlook: Cerus expects a 14% increase in revenue for 2025 and has provided guidance for 2026, reflecting the company's confidence in its strategic planning and future development.
- Market Reaction: Following the announcement, Cerus's stock price experienced a slight after-hours decline of 0.0% to $1.805, indicating a cautious market sentiment regarding the new CEO's appointment.
See More
Cerus (CERS) Q4 2025 Earnings Call Transcript
See More
